Foghorn Therapeutics Inc. (FHTX) Reports Q4 Loss, Beats Revenue Estimates

分组1 - Foghorn Therapeutics Inc. reported a quarterly loss of $0.34 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.28, representing an earnings surprise of -19.72% [1] - The company posted revenues of $9.25 million for the quarter ended December 2025, exceeding the Zacks Consensus Estimate by 14.87%, and showing significant growth from $2.86 million in the same quarter last year [2] - Over the last four quarters, Foghorn Therapeutics has surpassed consensus EPS estimates two times and topped consensus revenue estimates twice [2] 分组2 - The stock has increased by approximately 1.7% since the beginning of the year, while the S&P 500 has declined by 0.9% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.26 on revenues of $9.06 million, and for the current fiscal year, it is -$0.96 on revenues of $42.83 million [7] - The Zacks Industry Rank for Medical - Biomedical and Genetics is currently in the bottom 42% of over 250 Zacks industries, indicating potential underperformance compared to higher-ranked industries [8]